BetterLife Pharma Inc. has announced the appointment of Daniel Carcillo as Corporate Advisor to advance the development of BETR-001, the company's proprietary non-hallucinogenic derivative of LSD targeting traumatic brain injury, cluster headache, and migraine treatment. Carcillo brings unique firsthand experience to this role, having been forced to retire from professional hockey at age 30 due to Post Concussion Syndrome after sustaining seven concussions during his NHL career.
The significance of this appointment extends beyond corporate strategy, representing a convergence of lived experience and pharmaceutical innovation. Carcillo's background includes winning two Stanley Cups with the Chicago Blackhawks before creating a non-profit organization assisting former NHL players suffering from post-concussion syndrome and mental health issues. His previous role as founder and CEO of Wesana Health, a life sciences company leveraging psilocybin-based medicine for traumatic brain injuries, provides him with substantial industry expertise in psychedelic medicine development.
Carcillo emphasized the potential impact of BETR-001, stating that joining BetterLife represents the natural next step in his mission to help concussion survivors. He noted the medicine carries the promise of psychedelic healing without regulatory barriers while maintaining serotonergic benefits needed by patients. His personal experience with brain trauma informs his perspective on how powerful such breakthroughs could be for athletes, veterans, and anyone living with the invisible weight of concussion.
Dr. Ahmad Doroudian, CEO of BetterLife, expressed excitement about Carcillo joining the advisory group, highlighting that his firsthand experience with TBI and passion for advancing treatments will provide invaluable guidance. The collaboration aims to accelerate development of BETR-001, which is currently in preclinical and IND-enabling studies.
The therapeutic approach represents a significant advancement in neurological treatment accessibility. BETR-001's non-hallucinogenic and non-controlled status means it can potentially be self-administered, unlike traditional psychedelic treatments that require clinical supervision. BetterLife's synthesis patent eliminates regulatory hurdles, while pending composition and method of use patents cover treatment of various neurological disorders until approximately 2042. For more information about the company's developments, visit https://blifepharma.com.
This development could have substantial implications for the millions worldwide suffering from traumatic brain injuries, cluster headaches, and migraines. The non-hallucinogenic nature of BETR-001 addresses one of the primary barriers to psychedelic medicine adoption, potentially making effective neurological treatments more accessible to patients who cannot access or tolerate traditional psychedelic therapies. The involvement of someone with Carcillo's personal and professional experience in brain injury advocacy strengthens the credibility of this approach and may accelerate both development and public acceptance of innovative neurological treatments.
